Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL29107417 | 0.95 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL28205841 | 0.95 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL9394267 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL28440222 | 0.92 | SLC7A5 (0.56) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL29245680 | 0.92 | SLC7A5 (0.58) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL1551967 | 0.92 | SLC7A5 (0.61) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL20270917 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL27546004 | 0.91 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL28465850 | 0.90 | SLC7A5 (0.56) | NPY4RNPY1RNPY5RNPY2RSLC7A5 | |
| Tyrosine SCHEMBL26109113 | 0.90 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |